PTEN突变对子宫内膜癌患者预后和药物敏感性的影响  

Effect of PTEN Mutation in the Prognosis and Drug Sensitivity in Endometrial Cancer

作　　者：刘颖[1] 周锦橐 牛培广[1] 史道华[1] LIU Ying;ZHOU Jin-tuo;NIU Pei-guang;SHI Dao-hua(Fujian Maternity and Child Health Hospital,Affiliated Hospital of Fujian Medical University,Fuzhou 350001,China)

机构地区：[1]福建省妇幼保健院,福建医科大学附属医院,福建福州350001

出　　处：《海峡药学》2021年第12期123-126,共4页Strait Pharmaceutical Journal

基　　金：福建省卫生健康中青年骨干人才培养项目(2020GGA019)。

摘　　要：目的分析子宫内膜癌组织中PTEN突变及其对子宫内膜癌患者预后的影响,寻找对PTEN突变子宫内膜癌敏感的药物。方法利用cBioPortal数据库研究子宫内膜癌组织中PTEN突变情况及其对子宫内膜癌患者预后的影响。利用GDSC数据库寻找对PTEN突变子宫内膜癌敏感的药物。结果PTEN在子宫内膜癌组织中的突变频率为65.2%。与野生型相比,PTEN突变的子宫内膜癌患者总生存期和无进展生存期均延长。PTEN突变型和的野生型子宫内膜癌细胞对顺铂(P=0.055)和紫杉醇(P=0.09)的IC50无明显差异。PTEN突变型子宫内膜癌细胞对AKT激酶抑制剂Afuresertib(P=0.047)的敏感性增强。结论PTEN突变能够延长子宫内膜癌患者总生存期和无进展生存期,AKT激酶抑制剂Afuresertib有望成为PTEN突变子宫内膜癌患者的精准治疗药物。OBJECTIVE To analyze the effect of PTEN mutation in the prognosis and drug sensitivity in Endometrial cancer,to search drugs that sensitive to Endometrial cancer patients with PTEN mutation.METHODS We use cBioPortal database to analyze the effect of PTEN mutation in the prognosis of Endometrial cancer,GDSC dataset was used to identified the drugs that sensitive to cell lines with PTEN mutation.RESULTS Our results showed that PTEN mutation was carried in 65.2% of Endometrial cancer patients.Prognosis analysis showed that there were favorable overall survival and progression free survival in Endometrial cancer patients with PTEN mutation.Moreover,it was more sensitive to AKT inhibitor-Afuresertib-on Endometrial cancer cell lines with PTEN mutation than that with wild type.CONCLUSION There were favorable overall survival and progression free survival in Endometrial cancer patients with PTEN mutation,it is more sensitive to AKT inhibitor-Afuresertib-on Endometrial cancer cell lines with PTEN mutation than that with wild type.These results provide a potential target and therapeutic strategies for patients with PTEN mutation.

关 键 词：子宫内膜癌 PTEN突变 cBioPortal数据库 GDSC数据库 药物敏感性 

分 类 号：R969.4[医药卫生—药理学]